{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:54:47Z","timestamp":1787007287018,"version":"build-2736575974"},"reference-count":101,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2026,3,4]]},"DOI":"10.1080\/14737140.2025.2592735","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:40:27Z","timestamp":1763631627000},"page":"321-332","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Future directions for antibody-drug conjugates in urothelial cancer"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3060-6169","authenticated-orcid":false,"given":"Elisa","family":"D\u2019Agostino","sequence":"first","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pirola","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Callegari","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tonni","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Tchawa","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Matranga","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Ponzoni","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Oltrecolli","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Piombino","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pipitone","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Baldessari","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bacchelli","sequence":"additional","affiliation":[{"name":"University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Dominici","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]},{"name":"University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sabbatini","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppa","family":"Vitale","sequence":"additional","affiliation":[{"name":"University Hospital of Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"Global Cancer Observatory [Internet]. Lyon (FR): International Agency for Research on Cancer; 2023 [cited 2023 Apr 15]. Available from: https:\/\/gco.iarc.fr\/"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.07.033"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.020"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01524-7"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.006"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010131"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231192402"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.07.006"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.039"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.016"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179696"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1624-3"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.02.049"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0846"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01983"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2051"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.15130"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25615"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29060312"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-253"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3924"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951X-937"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043720"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210477"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(95)90086-1"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2016.06.007"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012659"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302377"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-180169"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119674"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041278"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2025.05.012"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1557"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176454"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02992-x"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1764"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3897-x"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0970"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk134"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0358"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S135571"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0403"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16921"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0900-z"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13253"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgac063"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0702"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0296"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0207"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0219"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.08.030"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207528"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0696"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3825"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.10.025"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205500"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03143-3"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.12.008"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2015.12.008"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-23-B041"},{"issue":"1","key":"e_1_3_4_67_1","first-page":"161","article-title":"Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers","volume":"13","author":"Li Y","year":"2023","unstructured":"Li Y, Li L, Fu H, et al. Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers. Am J Cancer Res. 2023 [cited 2023 Jan 15];13(1):161\u2013175.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30465-4"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02044"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140"},{"key":"e_1_3_4_72_1","volume-title":"ESMO Congress 2025","author":"Vulsteke C","year":"2025","unstructured":"Vulsteke C, Kaimakliotis HZ ,Danchaivijitr P, et al. Perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin-ineligible: phase 3 KEYNOTE-905 study. Abstract LBA2. ESMO Congress 2025.October 17-21, 2025. Berlin, Germany.2025."},{"key":"e_1_3_4_73_1","unstructured":"European Medicines Agency (EMA). Padcev INN\u2013enfortumab vedotin: epar assessment report \u2013 variation H-C-5392\/II\/0013 (addition of first-line indication with pembrolizumab). London: EMA; 2024 Jul 25. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/padcev-h-c-005392-ii-0013-epar-assessment-report-variation_en.pdf"},{"key":"e_1_3_4_74_1","unstructured":"U.S. Food and Drug Administration. Fda approves enfortumab vedotin\u2011ejfv in combination with pembrolizumab for locally advanced or metastatic urothelial cancer [internet]. Silver Spring (MD): FDA; 2023 Dec 15 [cited 2023 Dec 15]. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-enfortumab-vedotin-ejfv-combination-pembrolizumab"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.11.005"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03489"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.011"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-015-9552-6"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1513"},{"key":"e_1_3_4_84_1","unstructured":"U.S. Food and Drug Administration. Fda grants accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for unresectable or metastatic HER2-positive (IHC 3+) solid tumors in adult patients who have received prior systemic treatment and have no satisfactory alternative treatment options. Internet. Silver Spring (MD): FDA; 2024 Apr 5 [cited 2024 Apr 5]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-enhertu"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2019.12.027"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2069883"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.1028"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e16059"},{"issue":"16","key":"e_1_3_4_89_1","first-page":"4520","article-title":"Rc48-adc for metastatic urothelial carcinoma with HER2-positive expression: results from the phase II RC48-C005 study","volume":"38","author":"He Z","year":"2020","unstructured":"He Z, Sheng X, Ji Z, et al. Rc48-adc for metastatic urothelial carcinoma with HER2-positive expression: results from the phase II RC48-C005 study. J Clin Oncol. 2020;38(16_suppl):4520.","journal-title":"J Clin Oncol"},{"issue":"16","key":"e_1_3_4_90_1","first-page":"4520","article-title":"Rc48-adc for metastatic urothelial carcinoma with HER2-positive expression: results from the phase II RC48-C009 study","volume":"38","author":"He Z","year":"2020","unstructured":"He Z, Sheng X, Ji Z, et al. Rc48-adc for metastatic urothelial carcinoma with HER2-positive expression: results from the phase II RC48-C009 study. J Clin Oncol. 2020;38(16_suppl):4520.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02912"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100637"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511648"},{"key":"e_1_3_4_94_1","unstructured":"RemeGen Co. Ltd. JCO a top oncology journal published research results of disitamab vedotin in the treatment of urothelial cancer. Company press release; 2023 Nov 22 [cited 2025 Jul 27]."},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS594"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2052"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02457-8"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091594"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3151"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3159"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-5443"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-4835"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01146-x"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2025.2592735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:45:55Z","timestamp":1772765155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2025.2592735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1080\/14737140.2025.2592735"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2025.2592735","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}